Integrative Analysis of Pulmonary Sarcomatoid Carcinoma (PSC)

Not yet recruiting

• Conditions: Lung Cancer
• Interventions: Other: The investigators will extract total protein, DNA and RNA from PSC patients.

• Registration Number: NCT04215913
• Lead Sponsor: Shanghai 10th People's Hospital

Brief Summary

Integrative Analysis of pulmonary sarcomatoid carcinoma (PSC)

Detailed Description

The investigators will analyzed proteomes of paired normal lung tissues and pulmonary sarcomatoid carcinoma with or without metastasis, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal lung tissue, primary pulmonary sarcomatoid carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of lung cancer characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

Study Timeline

• Status Verified: 2019-12
• Study First Submitted: 2019-12-29
• Study First Submitted QC: 2019-12-29
• Last Update Submitted: 2019-12-29
• Study Start: 2019-12-30
• Study First Posted: 2020-01-02
• Last Update Posted: 2020-01-02
• Primary Completion: 2025-12-24
• Study Completion: 2025-12-24

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Age ≤ 70 years with histologically proven LCLC
• No severe major organ dysfunction
• World Health Organization (WHO) performance status of 0 or 1
• No prior cancer chemotherapy

Exclusion Criteria

• Age ≥ 70
• Severe major organ dysfunction
• WHO performance status of >1
• Prior cancer chemotherapy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Normal lung tissue	The investigators will extract total protein, DNA and RNA from PSC patients.	Normal lung tissue from PSC patients
PSC tissues	The investigators will extract total protein, DNA and RNA from PSC patients.	PSC tissues from PSC patients
Metastasis tissues	The investigators will extract total protein, DNA and RNA from PSC patients.	Metastasis tissues from PSC patients

Primary Outcome Measures

Name	Time	Method
10 years overall survival	10 years overall survival	10 years overall survival

Secondary Outcome Measures

Name	Time	Method
10 years disease-free survival	10 years disease-free survival	10 years disease-free survival

Trial Locations

Locations (1)

Da Fu; 🇨🇳 Shanghai, Shanghai, China